Genetic influences on neural plasticity

PM and R

Volumn 2, Issue 12 SUPPL, 2010, Pages

  Pearson Fuhrhop, Kristin M ^a   Cramer, Steven C ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; BRAIN DERIVED NEUROTROPHIC FACTOR; CATECHOL METHYLTRANSFERASE;

ANIMAL; ATTENTION; BRAIN; BRAIN DEPTH STIMULATION; DEPRESSION; GENETIC POLYMORPHISM; GENETICS; HUMAN; KINESIOTHERAPY; LEARNING; NERVE CELL PLASTICITY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; ROBOTICS; STROKE; TASK PERFORMANCE;

ANIMALS; APOLIPOPROTEINS E; ATTENTION; BRAIN; BRAIN-DERIVED NEUROTROPHIC FACTOR; CATECHOL O-METHYLTRANSFERASE; DEEP BRAIN STIMULATION; DEPRESSION; EXERCISE THERAPY; HUMANS; LEARNING; NEURONAL PLASTICITY; POLYMORPHISM, GENETIC; ROBOTICS; STROKE; TASK PERFORMANCE AND ANALYSIS;

EID: 79952279029     PISSN: 19341482     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pmrj.2010.09.011     Document Type: Review

References (246)

1. Gresham G, Duncan P, Stason W, et al. Post-Stroke Rehabilitation. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service, Agency for Health Care Policy and Research; 1995.
2. Rathore S, Hinn A, Cooper L, Tyroler H, Rosamond W. Characterization of incident stroke signs and symptoms: Findings from the atherosclerosis risk in communities study. Stroke 2002;33:2718-2721.
3. Cramer S, Bastings E. Mapping clinically relevant plasticity after stroke. Neuropharmacology 2000;39:842-851.
4. Frost S, Barbay S, Friel K, Plautz E, Nudo R. Reorganization of remote cortical regions after ischemic brain injury: A potential substrate for stroke recovery. J Neurophysiol 2003;89:3205-3214.
5. Rossini PM, Calautti C, Pauri F, Baron JC. Post-stroke plastic reorganisation in the adult brain. Lancet Neurol 2003;2:493-502.
6. Takahashi CD, Der Yeghiaian L, Cramer SC. Stroke recovery and its imaging. Neuroimaging Clin North Am 2005;15:681-695.
7. Ward NS, Cohen LG. Mechanisms underlying recovery of motor function after stroke. Arch Neurol 2004;61:1844-1848.
8. Cramer SC. Repairing the human brain after stroke: I. Mechanisms of spontaneous recovery. Ann Neurol 2008;63:272-287.
9. Yozbatiran N, Cramer SC. Imaging motor recovery after stroke. NeuroRx 2006;3:482-488.
10. Ethell IM, Pasquale EB. Molecular mechanisms of dendritic spine development and remodeling. Prog Neurobiol 2005;75:161-205.
11. Catterall WA, Dib-Hajj S, Meisler MH, Pietrobon D. Inherited neuronal ion channelopathies: New windows on complex neurological diseases. J Neurosci 2008;28:11768-11777.
12. Cull-Candy SG, Leszkiewicz DN. Role of distinct NMDA receptor subtypes at central synapses. Sci STKE 2004;255:re16.
13. Kessels HW, Malinow R. Synaptic AMPA receptor plasticity and behavior. Neuron 2009;61:340-350.
14. Bliss TV, Collingridge GL. A synaptic model of memory: Long-term potentiation in the hippocampus. Nature 1993;361:31-39.
15. Bailey CH, Kandel ER. Structural changes accompanying memory storage. Annu Rev Physiol 1993;55:397-426.
16. Herring A, Ambree O, Tomm M, et al. Environmental enrichment enhances cellular plasticity in transgenic mice with Alzheimer-like pathology. Exp Neurol 2009;216:184-192.
17. Volkmar F, Greenough W. Rearing complexity affects branching of dendrites in the visual cortex of the rat. Science 1972;176:1145-1147.
18. Chang FL, Greenough WT. Lateralized effects of monocular training on dendritic branching in adult split-brain rats. Brain Res 1982;232: 283-292.
19. Patel SN, Rose SP, Stewart MG. Training induced dendritic spine density changes are specifically related to memory formation processes in the chick, Gallus domesticus. Brain Res 1988;463:168-173.
20. Bailey CH, Chen M. Morphological basis of long-term habituation and sensitization in aplysia. Science 1983;220:91-93.
21. Agranoff BW, Davis RE, Brink JJ. Memory fixation in the goldfish. Proc Natl Acad Sci U S A 1965;54:788-793.
22. Bullock S, Csillag A, Rose SP. Synaptic vesicle proteins and acetylcholine levels in chick forebrain nuclei are altered by passive avoidance training. J Neurochem 1987;49:812-820.
23. Kuhl D, Kennedy TE, Barzilai A, Kandel ER. Long-term sensitization training in Aplysia leads to an increase in the expression of BiP, the major protein chaperon of the ER. J Cell Biol 1992;119:1069-1076.
24. Pohle W, Ruthrich HL, Popov N, Matthies H. Fucose incorporation into rat hippocampus structures after acquisition of a brightness discrimination. A histoautoradiographic analysis. Acta Biol Med Ger 1979;38:53-63.
25. Cheeran B, Talelli P, Mori F, et al. A common polymorphism in the brain-derived neurotrophic factor gene (BDNF) modulates human cortical plasticity and the response to rTMS. J Physiol 2008;586:5717-5725.
26. Chen R. Interactions between inhibitory and excitatory circuits in the human motor cortex. Exp Brain Res 2004;154:1-10.
27. Floel A, Breitenstein C, Hummel F, et al. Dopaminergic influences on formation of a motor memory. Ann Neurol 2005;58:121-130.
28. Kleim JA, Chan S, Pringle E, et al. BDNF val66met polymorphism is associated with modified experience-dependent plasticity in human motor cortex. Nat Neurosci 2006;9:735-737.
29. Reis J, Swayne OB, Vandermeeren Y, et al. Contribution of transcranial magnetic stimulation to the understanding of cortical mechanisms involved in motor control. J Physiol 2008;586:325-351.
30. Kleim J, Kleim E, Cramer S. Systematic assessment of training-induced changes in corticospinal output to hand using frameless stereotaxic transcranial magnetic stimulation. Nat Protoc 2007;2:1675-1684.
31. Merzenich MM, Jenkins WM. Reorganization of cortical representations of the hand following alterations of skin inputs induced by nerve injury, skin island transfers, and experience. J Hand Ther 1993;6:89-104.
32. Sanes J, Donoghue J. Plasticity and primary motor cortex. Annu Rev Neurosci 2000;23:393-415.
33. Nudo R, Milliken G, Jenkins W, Merzenich M. Use-dependent alterations of movement representations in primary motor cortex of adult squirrel monkeys. J Neurosci 1996;16:785-807.
34. Kleim JA, Barbay S, Nudo RJ. Functional reorganization of the rat motor cortex following motor skill learning. J Neurophysiol 1998;80: 3321-3325.
35. Kleim JA, Hogg TM, VandenBerg PM, Cooper NR, Bruneau R, Remple M. Cortical synaptogenesis and motor map reorganization occur during late, but not early, phase of motor skill learning. J Neurosci 2004;24:628-633.
36. Xerri C, Merzenich M, Peterson B, Jenkins W. Plasticity of primary somatosensory cortex paralleling sensorimotor skill recovery from stroke in adult monkeys. J Neurophysiol 1998;79:2119-2148.
37. Allard T, Clark SA, Jenkins WM, Merzenich MM. Reorganization of somatosensory area 3b representations in adult owl monkeys after digital syndactyly. J Neurophysiol 1991;66:1048-1058.
38. Jenkins WM, Merzenich MM, Ochs MT, Allard T, Guic-Robles E. Functional reorganization of primary somatosensory cortex in adult owl monkeys after behaviorally controlled tactile stimulation. J Neurophysiol 1990;63:82-104.
39. Nudo RJ, Wise BM, SiFuentes F, Milliken GW. Neural substrates for the effects of rehabilitative training on motor recovery after ischemic infarct. Science 1996;272:1791-1794.
40. Butefisch CM, Kleiser R, Seitz RJ. Post-lesional cerebral reorganisation: Evidence from functional neuroimaging and transcranial magnetic stimulation. J Physiol (Paris) 2006;99:437-454.
41. Nudo R. Functional and structural plasticity in motor cortex: Implications for stroke recovery. Phys Med Rehabil Clin North Am 2003; 14(1 Suppl):S57-S76.
42. Richards LG, Stewart KC, Woodbury ML, Senesac C, Cauraugh JH. Movement-dependent stroke recovery: A systematic review and metaanalysis of TMS and fMRI evidence. Neuropsychologia 2008;46:3-11.
43. Rossini P, Dal Forno G. Neuronal post-stroke plasticity in the adult. Restor Neurol Neurosci 2004;22:193-206.
44. Kleim JA, Jones TA. Principles of experience-dependent neural plasticity: Implications for rehabilitation after brain damage. J Speech Lang Hear Res 2008;51:S225-S239.
45. Nudo RJ. Plasticity. NeuroRx 2006;3:420-427.
46. Stein DG. Sex differences in brain damage and recovery of function: Experimental and clinical findings. Prog Brain Res 2007;161:339-351.
47. Barde YA. Neurotrophins: A family of proteins supporting the survival of neurons. Prog Clin Biol Res 1994;390:45-56.
48. Lewin GR. Neurotrophins and the specification of neuronal phenotype. Philos Trans R Soc Lond B Biol Sci 1996;351:405-411.
49. Thoenen H. The changing scene of neurotrophic factors. Trends Neurosci 1991;14:165-170.
50. Levine ES, Dreyfus CF, Black IB, Plummer MR. Brain-derived neurotrophic factor rapidly enhances synaptic transmission in hippocampal neurons via postsynaptic tyrosine kinase receptors. Proc Natl Acad Sci U S A 1995;92:8074-8077.
51. Lu B. BDNF and activity-dependent synaptic modulation. Learn Mem 2003;10:86-98.
52. Lohof AM, Ip NY, Poo MM. Potentiation of developing neuromuscular synapses by the neurotrophins NT-3 and BDNF. Nature 1993;363: 350-353.
53. Lessmann V. Neurotrophin-dependent modulation of glutamatergic synaptic transmission in the mammalian CNS. Gen Pharmacol 1998; 31:667-674.
54. Hartmann M, Heumann R, Lessmann V. Synaptic secretion of BDNF after high-frequency stimulation of glutamatergic synapses. EMBO J 2001;20:5887-5897.
55. Kafitz KW, Rose CR, Thoenen H, Konnerth A. Neurotrophin-evoked rapid excitation through TrkB receptors. Nature 1999;401:918-921.
56. Carter AR, Chen C, Schwartz PM, Segal RA. Brain-derived neurotrophic factor modulates cerebellar plasticity and synaptic ultrastructure. J Neurosci 2002;22:1316-1327.
57. Kang H, Schuman EM. Long-lasting neurotrophin-induced enhancement of synaptic transmission in the adult hippocampus. Science 1995;267:1658-1662.
58. Li YX, Zhang Y, Lester HA, Schuman EM, Davidson N. Enhancement of neurotransmitter release induced by brain-derived neurotrophic factor in cultured hippocampal neurons. J Neurosci 1998;18: 10231-10240.
59. Messaoudi E, Bardsen K, Srebro B, Bramham CR. Acute intrahippocampal infusion of BDNF induces lasting potentiation of synaptic transmission in the rat dentate gyrus. J Neurophysiol 1998;79:496-499.
60. Winter J. Brain derived neurotrophic factor, but not nerve growth factor, regulates capsaicin sensitivity of rat vagal ganglion neurones. Neurosci Lett 1998;241:21-24.
61. Desai NS, Rutherford LC, Turrigiano GG. BDNF regulates the intrinsic excitability of cortical neurons. Learn Mem 1999;6:284-291.
62. Schinder AF, Berninger B, Poo M. Postsynaptic target specificity of neurotrophin-induced presynaptic potentiation. Neuron 2000;25: 151-163.
63. Lu B, Chow A. Neurotrophins and hippocampal synaptic transmission and plasticity. J Neurosci Res 1999;58:76-87.
64. McAllister AK. Subplate neurons: A missing link among neurotrophins, activity, and ocular dominance plasticity? Proc Natl Acad Sci U S A 1999;96:13600-13602.
65. Altar CA, Fritsche M, Lindsay RM. Cell body infusions of brainderived neurotrophic factor increase forebrain dopamine release and serotonin metabolism determined with in vivo microdialysis. Adv Pharmacol 1998;42:915-921.
66. Linnarsson S, Bjorklund A, Ernfors P. Learning deficit in BDNF mutant mice. Eur J Neurosci 1997;9:2581-2587.
67. Ma YL, Wang HL, Wu HC, Wei CL, Lee EH. Brain-derived neurotrophic factor antisense oligonucleotide impairs memory retention and inhibits long-term potentiation in rats. Neuroscience 1998;82:957-967.
68. Minichiello L, Korte M, Wolfer D, et al. Essential role for TrkB receptors in hippocampus-mediated learning. Neuron 1999;24:401-414.
69. Mizuno M, Yamada K, Olariu A, Nawa H, Nabeshima T. Involvement of brain-derived neurotrophic factor in spatial memory formation and maintenance in a radial arm maze test in rats. J Neurosci 2000;20: 7116-7121.
70. Gorski JA, Zeiler SR, Tamowski S, Jones KR. Brain-derived neurotrophic factor is required for the maintenance of cortical dendrites. J Neurosci 2003;23:6856-6865.
71. Vaynman S, Gomez-Pinilla F. License to run: Exercise impacts functional plasticity in the intact and injured central nervous system by using neurotrophins. Neurorehabil Neural Repair 2005;19:283-295.
72. Genoud C, Knott GW, Sakata K, Lu B, Welker E. Altered synapse formation in the adult somatosensory cortex of brain-derived neurotrophic factor heterozygote mice. J Neurosci 2004;24:2394-2400.
73. Kleim JA, Jones TA, Schallert T. Motor enrichment and the induction of plasticity before or after brain injury. Neurochem Res 2003;28: 1757-1769.
74. VandenBerg PM, Bruneau RM, Thomas N, Kleim JA. BDNF is required for maintaining motor map integrity in adult cerebral cortex. Program No. 681.5. 2004 Neuroscience Meeting Planner. San Diego, CA: Society for Neuroscience, 2004. Online.
75. Kesslak JP, So V, Choi J, Cotman CW, Gomez-Pinilla F. Learning upregulates brain-derived neurotrophic factor messenger ribonucleic acid: A mechanism to facilitate encoding and circuit maintenance? Behav Neurosci 1998;112:1012-1019.
76. Gomez-Pinilla F, So V, Kesslak JP. Spatial learning induces neurotrophin receptor and synapsin I in the hippocampus. Brain Res 2001; 904:13-19.
77. Hall J, Thomas KL, Everitt BJ. Rapid and selective induction of BDNF expression in the hippocampus during contextual learning. Nat Neurosci 2000;3:533-535.
78. Rattiner LM, Davis M, French CT, Ressler KJ. Brain-derived neurotrophic factor and tyrosine kinase receptor B involvement in amygdaladependent fear conditioning. J Neurosci 2004;24:4796-4806.
79. Klintsova AY, Dickson E, Yoshida R, Greenough WT. Altered expression of BDNF and its high-affinity receptor TrkB in response to complex motor learning and moderate exercise. Brain Res 2004;1028: 92-104.
80. Rocamora N, Welker E, Pascual M, Soriano E. Upregulation of BDNF mRNA expression in the barrel cortex of adult mice after sensory stimulation. J Neurosci 1996;16:4411-4419.
81. Ishibashi H, Hihara S, Takahashi M, Heike T, Yokota T, Iriki A. Tool-use learning induces BDNF expression in a selective portion of monkey anterior parietal cortex. Brain Res Mol Brain Res 2002;102: 110-112.
82. Ishibashi H, Hihara S, Takahashi M, Heike T, Yokota T, Iriki A. Tool-use learning selectively induces expression of brain-derived neurotrophic factor, its receptor trkB, and neurotrophin 3 in the intraparietal multisensorycortex of monkeys. Brain Res Cogn Brain Res 2002;14:3-9.
83. Uchida K, Baba H, Maezawa Y, et al. Increased expression of neurotrophins and their receptors in the mechanically compressed spinal cord of the spinal hyperostotic mouse (twy/twy). Acta Neuropathol 2003;106:29-36.
84. Ferrer I, Krupinski J, Goutan E, Marti E, Ambrosio S, Arenas E. Brain-derived neurotrophic factor reduces cortical cell death by ischemia after middle cerebral artery occlusion in the rat. Acta Neuropathol (Berl) 2001;101:229-238.
85. Laske C, Stransky E, Leyhe T, et al. Stage-dependent BDNF serum concentrations in Alzheimer's disease. J Neural Transm 2006;113: 1217-1224.
86. Matzilevich DA, Rall JM, Moore AN, Grill RJ, Dash PK. High-density microarray analysis of hippocampal gene expression following experimental brain injury. J Neurosci Res 2002;67:646-663.
87. Comelli M, Seren M, Guidolin D, et al. Photochemical stroke and brain-derived neurotrophic factor (BDNF) mRNA expression. Neuroreport 1992;3:473-476.
88. Kurozumi K, Nakamura K, Tamiya T, et al. Mesenchymal stem cells that produce neurotrophic factors reduce ischemic damage in the rat middle cerebral artery occlusion model. Mol Ther 2005;11:96-104.
89. Miyake K, Yamamoto W, Tadokoro M, et al. Alterations in hippocampal GAP-43, BDNF, and L1 following sustained cerebral ischemia. Brain Res 2002;935:24-31.
90. Yamashita K, Wiessner C, Lindholm D, Thoenen H, Hossmann K. Post-occlusion treatment with BDNF reduces infarct size in a model of permanent occlusion of the middle cerebral artery in rat. Metab Brain Dis 1997;12:271-280.
91. Zhang Y, Pardridge WM. Blood-brain barrier targeting of BDNF improves motor function in rats with middle cerebral artery occlusion. Brain Res 2006;1111:227-229.
92. Zhao L, Risedal A, Wojcik A, Hejzlar J, Johansson B, Kokaia Z. Enriched environment influences brain-derived neurotrophic factor levels in rat forebrain after focal stroke. Neurosci Lett 2001;305:169-172.
93. Schabitz WR, Berger C, Kollmar R, et al. Effect of brain-derived neurotrophic factor treatment and forced arm use on functional motor recovery after small cortical ischemia. Stroke 2004;35:992-997.
94. Shimizu E, Hashimoto K, Iyo M. Ethnic difference of the BDNF 196G/A (val66met) polymorphism frequencies: The possibility to explain ethnic mental traits. Am J Med Genet B Neuropsychiatr Genet 2004;126:122-123.
95. Egan MF, Kojima M, Callicott JH, et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003;112:257-269.
96. Chen ZY, Patel PD, Sant G, et al. Variant brain-derived neurotrophic factor (BDNF) (Met66) alters the intracellular trafficking and activitydependent secretion of wild-type BDNF in neurosecretory cells and cortical neurons. J Neurosci 2004;24:4401-4411.
97. Ho BC, Milev P, O'Leary DS, Librant A, Andreasen NC, Wassink TH. Cognitive and magnetic resonance imaging brain morphometric correlates of brain-derived neurotrophic factor Val66Met gene polymorphism in patients with schizophrenia and healthy volunteers. Arch Gen Psychiatry 2006;63:731-740.
98. Pezawas L, Verchinski BA, Mattay VS, et al. The brain-derived neurotrophic factor val66met polymorphism and variation in human cortical morphology. J Neurosci 2004;24:10099-10102.
99. Szeszko PR, Lipsky R, Mentschel C, et al. Brain-derived neurotrophic factor val66met polymorphism and volume of the hippocampal formation. Mol Psychiatry 2005;10:631-636.
100. Bueller JA, Aftab M, Sen S, Gomez-Hassan D, Burmeister M, Zubieta JK. BDNF Val66Met allele is associated with reduced hippocampal volume in healthy subjects. Biol Psychiatry 2006;59:812-815.
101. Frodl T, Schule C, Schmitt G, et al. Association of the brain-derived neurotrophic factor Val66Met polymorphism with reduced hippocampal volumes in major depression. Arch Gen Psychiatry 2007; 64:410-416.
102. Nemoto K, Ohnishi T, Mori T, et al. The Val66Met polymorphism of the brain-derived neurotrophic factor gene affects age-related brain morphology. Neurosci Lett 2006;397:25-29.
103. Huang EJ, Reichardt LF. Neurotrophins: Roles in neuronal development and function. Annu Rev Neurosci 2001;24:677-736.
104. Lu B, Pang PT, Woo NH. The yin and yang of neurotrophin action. Nat Rev Neurosci 2005;6:603-614.
105. Hariri AR, Goldberg TE, Mattay VS, et al. Brain-derived neurotrophic factor val66met polymorphism affects human memory-related hippocampal activity and predicts memory performance. J Neurosci 2003;23:6690-6694.
106. Goldberg TE, Iudicello J, Russo C, et al. BDNF Val66Met polymorphism significantly affects d' in verbal recognition memory at short and long delays. Biol Psychol 2008;77:20-24.
107. McHughen SA, Rodriguez PF, Kleim JA, et al. BDNF val66met polymorphism influences motor system function in the human brain. Cereb Cortex 2010;20:1254-1262.
108. Laske C, Stransky E, Leyhe T, et al. Stage-dependent BDNF serum concentrations in Alzheimer's disease. J Neural Transm 2006;113: 1217-1224.
109. Siironen J, Juvela S, Kanarek K, Vilkki J, Hernesniemi J, Lappalainen J. The Met allele of the BDNF Val66Met polymorphism predicts poor outcome among survivors of aneurysmal subarachnoid hemorrhage. Stroke 2007;38:2858-2860.
110. Mahley RW, Rall SC, Jr.Apolipoprotein E: Far more than a lipid transport protein. Annu Rev Genomics Hum Genet 2000;1:507-537.
111. Cedazo-Minguez A. Apolipoprotein E and Alzheimer's disease: Molecular mechanisms and therapeutic opportunities. J Cell Mol Med 2007;11:1227-1238.
112. Eichner JE, Dunn ST, Perveen G, Thompson DM, Stewart KE, Stroehla BC. Apolipoprotein E polymorphism and cardiovascular disease: A HuGE review. Am J Epidemiol 2002;155:487-495.
113. Bersano A, Ballabio E, Bresolin N, Candelise L. Genetic polymorphisms for the study of multifactorial stroke. Hum Mutat 2008;29: 776-795.
114. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993;261:921-923.
115. Hyman BT, Gomez-Isla T, Rebeck GW, et al. Epidemiological, clinical, and neuropathological study of apolipoprotein E genotype in Alzheimer's disease. Ann N Y Acad Sci 1996;802:1-5.
116. Caselli RJ, Graff-Radford NR, Reiman EM, et al. Preclinical memory decline in cognitively normal apolipoprotein E-epsilon4 homozygotes. Neurology 1999;53:201-207.
117. De Blasi S, Montesanto A, Martino C, et al. APOE polymorphism affects episodic memory among non demented elderly subjects. Exp Gerontol 2009;44:224-227.
118. Plassman BL, Welsh-Bohmer KA, Bigler ED, et al. Apolipoprotein E epsilon 4 allele and hippocampal volume in twins with normal cognition. Neurology 1997;48:985-989.
119. Burggren AC, Zeineh MM, Ekstrom AD, et al. Reduced cortical thickness in hippocampal subregions among cognitively normal apolipoprotein E e4 carriers. Neuroimage 2008;41:1177-1183.
120. Mueller SG, Schuff N, Raptentsetsang S, Elman J, Weiner MW. Selective effect of Apo e4 on CA3 and dentate in normal aging and Alzheimer's disease using high resolution MRI at 4 T. Neuroimage 2008;42:42-48.
121. Greenwood PM, Lambert C, Sunderland T, Parasuraman R. Effects of apolipoprotein E genotype on spatial attention, working memory, and their interaction in healthy, middle-aged adults: Results from the National Institute of Mental Health's BIOCARD study. Neuropsychology 2005;19:199-211.
122. Bondi MW, Salmon DP, Monsch AU, et al. Episodic memory changes are associated with the APOE-epsilon 4 allele in nondemented older adults. Neurology 1995;45:2203-2206.
123. Parasuraman R, Greenwood PM, Sunderland T. The apolipoprotein E gene, attention, and brain function. Neuropsychology 2002;16:254-274.
124. Reiman EM, Caselli RJ, Yun LS, et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med 1996;334:752-758.
125. Xu G, McLaren DG, Ries ML, et al. The influence of parental history of Alzheimer's disease and apolipoprotein E epsilon4 on the BOLD signal during recognition memory. Brain 2009;132:383-391.
126. Nathan BP, Nisar R, Randall S, et al. Apolipoprotein E is upregulated in olfactory bulb glia following peripheral receptor lesion in mice. Exp Neurol 2001;172:128-136.
127. Nwosu I, Gairhe S, Struble RG, Nathan BP. Impact of apoE deficiency during synaptic remodeling in the mouse olfactory bulb. Neurosci Lett 2008;441:282-285.
128. Chen Y, Durakoglugil MS, Xian X, Herz J. ApoE4 reduces glutamate receptor function and synaptic plasticity by selectively impairing ApoE receptor recycling. Proc Natl Acad Sci U S A 107:12011-12016.
129. White F, Nicoll JA, Roses AD, Horsburgh K. Impaired neuronal plasticity in transgenic mice expressing human apolipoprotein E4 compared to E3 in a model of entorhinal cortex lesion. Neurobiol Dis 2001;8:611-625.
130. Holtzman DM, Pitas RE, Kilbridge J, et al. Low density lipoprotein receptor-related protein mediates apolipoprotein E-dependent neurite outgrowth in a central nervous system-derived neuronal cell line. Proc Natl Acad Sci U S A 1995;92:9480-9484.
131. Arendt T, Schindler C, Bruckner MK, et al. Plastic neuronal remodeling is impaired in patients with Alzheimer's disease carrying apolipoprotein epsilon 4 allele. J Neurosci 1997;17:516-529.
132. Teasdale GM, Nicoll JA, Murray G, Fiddes M. Association of apolipoprotein E polymorphism with outcome after head injury. Lancet 1997;350:1069-1071.
133. Zhou W, Xu D, Peng X, Zhang Q, Jia J, Crutcher KA. Meta-analysis of APOE4 allele and outcome after traumatic brain injury. J Neurotrauma 2008;25:279-290.
134. Martinez-Gonzalez NA, Sudlow CL. Effects of apolipoprotein E genotype on outcome after ischaemic stroke, intracerebral haemorrhage and subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry 2006;77:1329-1335.
135. Cramer SC, Warren M, Enney L, Sanaee N, Hancock S, Procaccio V. Polymorphisms in BDNF and ApoE relate to clinical outcome in the GAIN Trials [abstract]. International Stroke Conference; 2009; San Diego. Stroke. 2009:40:e28.
136. Matthews PM, Johansen-Berg H, Reddy H. Non-invasive mapping of brain functions and brain recovery: Applying lessons from cognitive neuroscience to neurorehabilitation. Restor Neurol Neurosci 2004; 22:245-260.
137. Dobkin B. The Clinical Science of Neurologic Rehabilitation. New York: Oxford University Press; 2003.
138. Krakauer JW. Motor learning: Its relevance to stroke recovery and neurorehabilitation. Curr Opin Neurol 2006;19:84-90.
139. Mattay VS, Goldberg TE, Fera F, et al. Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc Natl Acad Sci U S A 2003;100:6186-6191.
140. Weinberger NM. Specific long-term memory traces in primary auditory cortex. Nat Rev Neurosci 2004;5:279-290.
141. Stefan K, Wycislo M, Classen J. Modulation of associative human motor cortical plasticity by attention. J Neurophysiol 2004;92:66-72.
142. Bobb AJ, Addington AM, Sidransky E, et al. Support for association between ADHD and two candidate genes: NET1 and DRD1. Am J Med Genet B Neuropsychiatr Genet 2005;134:67-72.
143. Shaw P, Gornick M, Lerch J, et al. Polymorphisms of the dopamine D4 receptor, clinical outcome, and cortical structure in attentiondeficit/ hyperactivity disorder. Arch Gen Psychiatry 2007;64:921-931.
144. Faraone SV, Perlis RH, Doyle AE, et al. Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry 2005;57:1313-1323.
145. Kirley A, Lowe N, Hawi Z, et al. Association of the 480 bp DAT1 allele with methylphenidate response in a sample of Irish children with ADHD. Am J Med Genet B Neuropsychiatr Genet 2003;121B:50-54.
146. Cook EH, Jr., Stein MA, Krasowski MD, et al. Association of attentiondeficit disorder and the dopamine transporter gene. Am J Hum Genet 1995;56:993-998.
147. Curran S, Mill J, Tahir E, et al. Association study of a dopamine transporter polymorphism and attention deficit hyperactivity disorder in UK and Turkish samples. Mol Psychiatry 2001;6:425-428.
148. Xu X, Mill J, Sun B, et al. Association study of promoter polymorphisms at the dopamine transporter gene in attention deficit hyperactivity disorder. BMC Psychiatry 2009;9:3.
149. Kopeckova M, Paclt I, Goetz P. Polymorphisms and low plasma activity of dopamine-beta-hydroxylase in ADHD children. Neuro Endocrinol Lett 2006;27:748-754.
150. Thapar A, O'Donovan M, Owen MJ. The genetics of attention deficit hyperactivity disorder. Hum Mol Genet 2005;14:R275-282.
151. Brookes KJ, Hawi Z, Kirley A, Barry E, Gill M, Kent L. Association of the steroid sulfatase (STS) gene with attention deficit hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet 2008;147B:1531-1535.
152. Bellgrove MA, Mattingley JB. Molecular genetics of attention. Ann N Y Acad Sci 2008;1129:200-212.
153. Greenwood PM, Sunderland T, Putnam K, Levy J, Parasuraman R. Scaling of visuospatial attention undergoes differential longitudinal change as a function of APOE genotype prior to old age: Results from the NIMH BIOCARD study. Neuropsychology 2005;19:830-840.
154. Belmaker RH, Agam G. Major depressive disorder. N Engl J Med 2008;358:55-68.
155. Hadidi N, Treat-Jacobson DJ, Lindquist R. Poststroke depression and functional outcome: A critical review of literature. Heart Lung 2009; 38:151-162.
156. Morris PL, Robinson RG, Andrzejewski P, Samuels J, Price TR. Association of depression with 10-year poststroke mortality. Am J Psychiatry 1993;150:124-129.
157. aan het Rot M, Mathew SJ, Charney DS. Neurobiological mechanisms in major depressive disorder. Can Med Assoc J 2009;180:305-313.
158. Hirschfeld RM. History and evolution of the monoamine hypothesis of depression. J Clin Psychiatry 2000;61(Suppl 6):4-6.
159. Levinson DF. The genetics of depression: A review. Biol Psychiatry 2006;60:84-92.
160. Baune BT, Dannlowski U, Domschke K, et al. The interleukin 1 beta (IL1B) gene is associated with failure to achieve remission and impaired emotion processing in major depression. Biol Psychiatry 2010; 67:543-549.
161. Uher R, Perroud N, Ng MY, et al. Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am J Psychiatry 2010;167:555-564.
162. McMahon FJ, Buervenich S, Charney D, et al. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet 2006;78:804-814.
163. Martinowich K, Manji H, Lu B. New insights into BDNF function in depression and anxiety. Nat Neurosci 2007;10:1089-1093.
164. Hwang JP, Tsai SJ, Hong CJ, Yang CH, Lirng JF, Yang YM. The Val66Met polymorphism of the brain-derived neurotrophic-factor gene is associated with geriatric depression. Neurobiol Aging 2006; 27:1834-1837.
165. Taylor WD, Zuchner S, McQuoid DR, Steffens DC, Speer MC, Krishnan KR. Allelic differences in the brain-derived neurotrophic factor Val66Met polymorphism in late-life depression. Am J Geriatr Psychiatry 2007;15:850-857.
166. Tsai SJ, Cheng CY, Yu YW, Chen TJ, Hong CJ. Association study of a brain-derived neurotrophic-factor genetic polymorphism and major depressive disorders, symptomatology, and antidepressant response. Am J Med Genet B Neuropsychiatr Genet 2003;123B:19-22.
167. Hong CJ, Huo SJ, Yen FC, Tung CL, Pan GM, Tsai SJ. Association study of a brain-derived neurotrophic-factor genetic polymorphism and mood disorders, age of onset and suicidal behavior. Neuropsychobiology 2003;48:186-189.
168. Schumacher J, Jamra RA, Becker T, et al. Evidence for a relationship between genetic variants at the brain-derived neurotrophic factor (BDNF) locus and major depression. Biol Psychiatry 2005;58:307-314.
169. Chen B, Dowlatshahi D, MacQueen GM, Wang JF, Young LT. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry 2001;50:260-265.
170. Bocchio-Chiavetto L, Miniussi C, Zanardini R, et al. 5-HTTLPR and BDNF Val66Met polymorphisms and response to rTMS treatment in drug resistant depression. Neurosci Lett 2008;437:130-134.
171. Neeper SA, Gomez-Pinilla F, Choi J, Cotman CW. Physical activity increases mRNA for brain-derived neurotrophic factor and nerve growth factor in rat brain. Brain Res 1996;726:49-56.
172. Gomez-Pinilla F, Ying Z, Roy RR, Molteni R, Edgerton VR. Voluntary exercise induces a BDNF-mediated mechanism that promotes neuroplasticity. J Neurophysiol 2002;88:2187-2195.
173. Vaynman S, Ying Z, Gomez-Pinilla F. Exercise induces BDNF and synapsin I to specific hippocampal subfields. J Neurosci Res 2004;76: 356-362.
174. Ploughman M, Granter-Button S, Chernenko G, Tucker BA, Mearow KM, Corbett D. Endurance exercise regimens induce differential effects on brain-derived neurotrophic factor, synapsin-I and insulinlike growth factor I after focal ischemia. Neuroscience 2005;136:991-1001.
175. Rojas Vega S, Abel T, Lindschulten R, Hollmann W, Bloch W, Struder HK. Impact of exercise on neuroplasticity-related proteins in spinal cord injured humans. Neuroscience 2008;153:1064-1070
176. Bryan A, Hutchison KE, Seals DR, Allen DL A transdisciplinary model integrating genetic, physiological, and psychological correlates of voluntary exercise. Health Psychol 2007;26:30-39.
177. Mata J, Thompson RJ, Gotlib IH. BDNF genotype moderates the relation between physical activity and depressive symptoms. Health Psychol 2010;29:130-133.
178. Freedman JE, Hylek EM. Clopidogrel, genetics, and drug responsiveness. N Engl J Med 2009;360:411-413.
179. Dam M, Tonin P, De Boni A, et al. Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy. Stroke 1996;27:1211-1214.
180. Jorge RE, Acion L, Moser D, Adams HP Jr., Robinson RG. Escitalopram and enhancement of cognitive recovery following stroke. Arch Gen Psychiatry 2010;67:187-196.
181. Pariente J, Loubinoux I, Carel C, et al. Fluoxetine modulates motor performance and cerebral activation of patients recovering from stroke. Ann Neurol 2001;50:718-729.
182. Robinson RG, Jorge RE, Moser DJ, et al. Escitalopram and problemsolving therapy for prevention of poststroke depression: A randomized controlled trial. JAMA 2008;299:2391-2400.
183. Zittel S, Weiller C, Liepert J. Citalopram improves dexterity in chronic stroke patients. Neurorehabil Neural Repair 2008;22:311-314.
184. Zittel S, Weiller C, Liepert J. Reboxetine improves motor function in chronic stroke. A pilot study. J Neurol 2007;254:197-201.
185. Walker-Batson D, Smith P, Curtis S, Unwin H, Greenlee R. Amphetamine paired with physical therapy accelerates motor recovery after stroke. Further evidence. Stroke 1995;26:2254-2259.
186. Restemeyer C, Weiller C, Liepert J. No effect of a levodopa single dose on motor performance and motor excitability in chronic stroke. A double-blind placebo-controlled cross-over pilot study. Restor Neurol Neurosci 2007;25:143-150.
187. Scheidtmann K, Fries W, Muller F, Koenig E. Effect of levodopa in combination with physiotherapy on functional motor recovery after stroke: A prospective, randomised, double-blind study. Lancet 2001; 358:787-790.
188. Grade C, Redford B, Chrostowski J, Toussaint L, Blackwell B. Methylphenidate in early poststroke recovery: A double-blind, placebocontrolled study. Arch Phys Med Rehabil 1998;79:1047-1050.
189. Stein MA, Waldman ID, Sarampote CS, et al. Dopamine transporter genotype and methylphenidate dose response in children with ADHD. Neuropsychopharmacology 2005;30:1374-1382.
190. Gilbert DL, Wang Z, Sallee FR, et al. Dopamine transporter genotype influences the physiological response to medication in ADHD. Brain 2006;129:2038-2046.
191. Peters EJ, Slager SL, McGrath PJ, Knowles JA, Hamilton SP. Investigation of serotonin-related genes in antidepressant response. Mol Psychiatry 2004;9:879-889.
192. Peters EJ, Slager SL, Jenkins GD, et al. Resequencing of serotoninrelated genes and association of tagging SNPs to citalopram response. Pharmacogenet Genomics 2009;19:1-10.
193. Smits KM, Smits LJ, Schouten JS, Stelma FF, Nelemans P, Prins MH. Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: A systematic review. Mol Psychiatry 2004;9:433-441.
194. Li-Wan-Po A, Girard T, Farndon P, Cooley C, Lithgow J. Pharmacogenetics of CYP2C19: Functional and clinical implications of a new variant CYP2C1917. Br J Clin Pharmacol 2010;69:222-230.
195. Hiratsuka M, Sasaki T, Mizugaki M. Genetic testing for pharmacogenetics and its clinical application in drug therapy. Clin Chim Acta 2006;363:177-186.
196. Holmes DR, Jr., Dehmer GJ, Kaul S, Leifer D, O'Gara PT, Stein CM. ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA "Boxed Warning." A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association. Circulation 2010;122:537-557.
197. Ikeda T, Kurosawa M, Uchikawa C, Kitayama S, Nukina N. Modulation of monoamine transporter expression and function by repetitive transcranial magnetic stimulation. Biochem Biophys Res Commun 2005;327:218-224.
198. Fritsch B, Reis J, Martinowich K, et al. Direct current stimulation promotes BDNF-dependent synaptic plasticity: Potential implications for motor learning. Neuron 29;66:198-204.
199. Reinkensmeyer DJ, Emken JL, Cramer SC. Robotics, motor learning, and neurologic recovery. Annu Rev Biomed Eng 2004;6:497-525.
200. Volpe BT, Ferraro M, Krebs HI, Hogan N. Robotics in the rehabilitation treatment of patients with stroke. Curr Atheroscler Rep 2002;4: 270-276.
201. Volpe BT, Krebs HI, Hogan N. Robot-aided sensorimotor training in stroke rehabilitation. Adv Neurol. 2003;92:429-433.
202. Takahashi CD, Der-Yeghiaian L, Le V, Motiwala RR, Cramer SC. Robot-based hand motor therapy after stroke. Brain 2008;131:425-437.
203. Bath KG, Lee FS. Variant BDNF (Val66Met) impact on brain structure and function. Cogn Affect Behav Neurosci 2006;6:79-85.
204. Jonsson E, Brene S, Zhang XR, et al. Schizophrenia and neurotrophin-3 alleles. Acta Psychiatr Scand 1997;95:414-419.
205. Virgos C, Martorell L, Valero J, et al. Association study of schizophrenia with polymorphisms at six candidate genes. Schizophr Res 15 2001;49:65-71.
206. Chen Z, Simmons MS, Perry RT, Wiener HW, Harrell LE, Go RC. Genetic association of neurotrophic tyrosine kinase receptor type 2 (NTRK2) with Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet 2008;147:363-369.
207. Tully K, Bolshakov VY. Emotional enhancement of memory: How norepinephrine enables synaptic plasticity. Mol Brain 2010;3:15.
208. Baffa A, Hohoff C, Baune BT, et al. Norepinephrine and serotonin transporter genes: Impact on treatment response in depression. Neuropsychobiology 2010;62:121-131.
209. Eisenhofer G. The role of neuronal and extraneuronal plasma membrane transporters in the inactivation of peripheral catecholamines. Pharmacol Ther 2001;91:35-62.
210. Breitenstein C, Floel A, Korsukewitz C, Wailke S, Bushuven S, Knecht S. A shift of paradigm: From noradrenergic to dopaminergic modulation of learning? J Neurol Sci 2006;248:42-47.
211. Bonifacio MJ, Palma PN, Almeida L, Soares-da-Silva P. Catechol-Omethyltransferase and its inhibitors in Parkinson's disease. CNS Drug Rev 2007;13:352-379.
212. Lotta T, Vidgren J, Tilgmann C, et al. Kinetics of human soluble and membrane-bound catechol O-methyltransferase: A revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 1995;34:4202-4210.
213. Egan MF, Goldberg TE, Kolachana BS, et al. Effect of COMT Val108/ 158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci U S A 2001;98:6917-6922.
214. Mannisto PT, Kaakkola S. Catechol-O-methyltransferase (COMT): Biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev 1999;51:593-628.
215. Xu H, Kellendonk CB, Simpson EH, et al. DRD2 C957T polymorphism interacts with the COMT Val158Met polymorphism in human working memory ability. Schizophr Res 2007;90:104-107.
216. Srivastava V, Varma PG, Prasad S, et al. Genetic susceptibility to tardive dyskinesia among schizophrenia subjects: IV. Role of dopaminergic pathway gene polymorphisms. Pharmacogenet Genomics 2006;16:111-117.
217. Caldu X, Vendrell P, Bartres-Faz D, et al. Impact of the COMT Val108/158 Met and DAT genotypes on prefrontal function in healthy subjects. Neuroimage 2007;37:1437-1444.
218. Raz N, Rodrigue KM, Kennedy KM, Land S. Genetic and vascular modifiers of age-sensitive cognitive skills: Effects of COMT, BDNF, ApoE, and hypertension. Neuropsychology 2009;23:105-116.
219. Mata I, Arranz MJ, Staddon S, Lopez-Ilundain JM, Tabares-Seisdedos R, Murray RM. The high-activity Val allele of the catechol-O-methyltransferase gene predicts greater cognitive deterioration in patients with psychosis. Psychiatr Genet 2006;16:213-216.
220. Galderisi S, Maj M, Kirkpatrick B, et al. Catechol-O-methyltransferase Val158Met polymorphism in schizophrenia: Associations with cognitive and motor impairment. Neuropsychobiology 2005;52:83-89.
221. de Frias CM, Annerbrink K, Westberg L, Eriksson E, Adolfsson R, Nilsson LG. Catechol O-methyltransferase Val158Met polymorphism is associated with cognitive performance in nondemented adults. J Cogn Neurosci 2005;17:1018-1025.
222. Starr JM, Fox H, Harris SE, Deary IJ, Whalley LJ. COMT genotype and cognitive ability: A longitudinal aging study. Neurosci Lett 2007;421: 57-61.
223. Luria A. Restoration of Function After Brain Injury. New York: Macmillan; 1963.
224. Burgard EC, Sarvey JM. Muscarinic receptor activation facilitates the induction of long-term potentiation (LTP) in the rat dentate gyrus. Neurosci Lett 1990;116:34-39.
225. Hasselmo ME, Barkai E. Cholinergic modulation of activity-dependent synaptic plasticity in the piriform cortex and associative memory function in a network biophysical simulation. J Neurosci 1995;15: 6592-6604.
226. Markram H, Segal M. Acetylcholine potentiates responses to Nmethyl-D-aspartate in the rat hippocampus. Neurosci Lett 1990;113: 62-65.
227. Atri A, Sherman S, Norman K, et al. Blockade of central cholinergic receptors impairs new learning and increases proactive interference in a word paired-associate memory task. Behav Neurosci 2004;118:223-236.
228. Beatty WW, Butters N, Janowsky DS. Patterns of memory failure after scopolamine treatment: Implications for cholinergic hypotheses of dementia. Behav Neural Biol 1986;45:196-211.
229. Flicker C, Serby M, Ferris SH. Scopolamine effects on memory, language, visuospatial praxis and psychomotor speed. Psychopharmacology (Berl) 1990;100:243-250.
230. Rogers JL, Kesner RP. Cholinergic modulation of the hippocampus during encoding and retrieval. Neurobiol Learn Mem 2003;80:332-342.
231. Elrod K, Buccafusco JJ, Jackson WJ. Nicotine enhances delayed matching-to-sample performance by primates. Life Sci 1988;43:277-287.
232. Poltavski DV, Petros T. Effects of transdermal nicotine on prose memory and attention in smokers and nonsmokers. Physiol Behav 2005;83:833-843.
233. Socci DJ, Sanberg PR, Arendash GW. Nicotine enhances Morris water maze performance of young and aged rats. Neurobiol Aging 1995;16: 857-860.
234. Warburton DM, Rusted JM, Muller C. Patterns of facilitation of memory by nicotine. Behav Pharmacol 1992;3:375-378.
235. Wesnes K, Warburton DM. Effects of scopolamine and nicotine on human rapid information processing performance. Psychopharmacology (Berl) 1984;82:147-150.
236. Giocomo LM, Hasselmo ME. Neuromodulation by glutamate and acetylcholine can change circuit dynamics by regulating the relative influence of afferent input and excitatory feedback. Mol Neurobiol 2007;36:184-200.
237. Scacchi R, Gambina G, Moretto G, Corbo RM. Variability of AChE, BChE, and ChAT genes in the late-onset form of Alzheimer's disease and relationships with response to treatment with Donepezil and Rivastigmine. Am J Med Genet B Neuropsychiatr Genet 2009;150B: 502-507.
238. Steinlein OK, Bertrand D. Neuronal nicotinic acetylcholine receptors: From the genetic analysis to neurological diseases. Biochem Pharmacol 2008;76:1175-1183.
239. Stitzel JA. Naturally occuring genetic variability in the nicotinic acetylcholine receptor alpha4 and alpha7 subunit genes and phenotypic diversity in humans and mice. Front Biosci 2008;13:477-491.
240. Edwards MJ, Huang YZ, Mir P, Rothwell JC, Bhatia KP. Abnormalities in motor cortical plasticity differentiate manifesting and nonmanifesting DYT1 carriers. Mov Disord 2006;21:2181-2186.
241. Hegde AN. Ubiquitin-proteasome-mediated local protein degradation and synaptic plasticity. Prog Neurobiol 2004;73:311-357.
242. Wood MA, Kaplan MP, Brensinger CM, Guo W, Abel T. Ubiquitin C-terminal hydrolase L3 (Uchl3) is involved in working memory. Hippocampus 2005;15:610-621.
243. Liu Y, Fallon L, Lashuel HA, Liu Z, Lansbury PT, Jr.The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility. Cell 2002;111: 209-218.
244. Meigs JB, Shrader P, Sullivan LM, et al. Genotype score in addition to common risk factors for prediction of type 2 diabetes. N Engl J Med 2008;359:2208-2219.
245. Pharoah PD, Antoniou AC, Easton DF, Ponder BA. Polygenes, risk prediction, and targeted prevention of breast cancer. N Engl J Med 2008;358:2796-2803.
246. Zheng SL, Sun J, Wiklund F, et al. Cumulative association of five genetic variants with prostate cancer. N Engl J Med 2008;358:910-919.